Biosight Pharma is a private, clinical-stage biotech company focused on developing innovative therapeutics for hematological malignancies and disorders. The company primarily serves patients with life-threatening diseases such as acute myeloid leukemia (AML), particularly targeting older patients who are unfit for standard chemotherapy. Operating in the oncology and hematology markets, Biosight Pharma's business model revolves around the research, development, and clinical trials of novel drug candidates. The company's lead product, BST-236 (aspacytarabine), is an advanced anti-metabolite designed to enable high-dose therapy with reduced systemic toxicity, aiming to provide safer and more effective treatment options. Revenue generation is expected through the successful commercialization of its drug candidates, either independently or through partnerships with larger pharmaceutical companies.

Keywords: AML, acute myeloid leukemia, chemotherapy, clinical trial, hematology, innovative, oncology, prodrugs, biotech, therapeutics.